BioSpace News Archive

The project will focus on and design a cost effective commercial manufacturing strategy for Rexgenero’s novel autologous cell therapy REX-001.

Patients are being scheduled for final study visits commencing March 1, 2018. Amarin maintains its guidance to report top-line results from the study before the end of Q3 2018.

A possible result of the investigation may also be that Orion Diagnostica will continue as a part of the Orion Group.

This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of new drugs.

Management will host a conference call at 5:00 p.m. Eastern Time on February 28th to discuss the results of the fourth quarter and fiscal year 2017, and to host a question and answer session.

The reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018.

This consists of equity capital of $872K from a group of investors comprising Spinventure SA, Gesval, private investors including Jean-Pierre Delwart and members of the Be Angels network.

UBS Investment Bank, Canaccord Genuity and Stifel were acting as joint book-running managers for the offering.

The combined portfolio of industry-leading passive temperature control packaging systems and thermal protection products will reinforce both companies’ ability to support their customers’ requirements for cold chain packaging solutions, and further expand ability to provide critical technical support on a global basis.

Innovatus Imaging is launching the new face of its combined global brand at the dawn of the new year.